Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Linise Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution profile is narrow, with activity limited to 1 distinct art unit and 1 distinct examiner. This suggests that the company is currently focusing its resources on a specific pharmaceutical or biological technology.
JOSEPH RANKIN SPANGLER is the busiest examiner for this portfolio, handling 1 pending office action. With only 1 examiner involved in the company's pending matters, the prosecution strategy is highly centralized. The involvement of 1 art unit indicates that the company's current patenting efforts are not spread across different technical departments at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPANGLER, JOSEPH RANKIN | 1 | 41.2% | +69.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17423197 | METHOD FOR MANUFACTURING PROTEOGLYCAN-CONTAINING COMPOSITION, AND PROTEOGLYCAN-CONTAINING COMPOSITION | SPANGLER, JOSEPH RANKIN | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17423197 | METHOD FOR MANUFACTURING PROTEOGLYCAN-CONTAINING COMPOSITION, AND PROTEOGLYCAN-CONTAINING COMPOSITION | SPANGLER, JOSEPH RANKIN | 1656 | §103 | Final Rejection | — | Pending | Jul 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLinise Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph Rankin Spangler has the most, with 1 of Linise Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.